{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:49Z","timestamp":1792787809125,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"German Ministry of Health"},{"name":"German Federal Institute for Drugs and Medical Devices","id":[{"id":"https:\/\/ror.org\/05ex5vz81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.semarthrit.2016.05.004","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T17:58:05Z","timestamp":1464285485000},"page":"238-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data"],"prefix":"10.1016","volume":"46","author":[{"given":"Maria","family":"Hoeltzenbein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Rajwanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"G\u00f8testam Skorpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"Berber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"\u00d8stensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2016.05.004_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-540-73259-4_7","article-title":"Humanized antihuman IL-6 receptor antibody, tocilizumab","volume":"181","author":"Nishimoto","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib2","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12272-015-0569-8","article-title":"IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future","volume":"38","author":"Kim","year":"2015","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib4","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/bdrb.21019","article-title":"The effects of interleukin-6 signal blockade on fertility, embryo-fetal development, and immunization in vivo","volume":"95","author":"Sakurai","year":"2012","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib7","unstructured":"Food and Drug Administration (FDA). Actemra drug approval package. Pharmacology review. \u3008http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/125276s000TOC.cfm\u3009 [accessed 28.03.16]."},{"key":"10.1016\/j.semarthrit.2016.05.004_bib8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/rheumatology\/ket409","article-title":"Biologic therapies and pregnancy: the story so far","volume":"53","author":"Hyrich","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(14)60932-6","article-title":"International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project","volume":"384","author":"Villar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10995-006-0073-3","article-title":"Pregnancy outcomes in women with rheumatoid arthritis in Washington State","volume":"10","author":"Reed","year":"2006","journal-title":"Matern Child Health J"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib11","unstructured":"World Health Organisation (WHO). Congenital anomalies. \u3008http:\/\/www.who.int\/mediacentre\/factsheets\/fs370\/en\/\u3009 [accessed 2.03.16]."},{"key":"10.1016\/j.semarthrit.2016.05.004_bib12","unstructured":"European surveillance of congenital anomalies (EUROCAT). Prevalence tables. \u3008http:\/\/www.eurocat-network.eu\/accessprevalencedata\/prevalencetable\u3009 [accessed 28.03.16]."},{"key":"10.1016\/j.semarthrit.2016.05.004_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00404-001-0265-4","article-title":"Malformations in newborn: results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990\u20131998)","volume":"266","author":"Queisser-Luft","year":"2002","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/bdra.20572","article-title":"Measurements of birth defect prevalence: which is most useful as a comparator group for pharmaceutical pregnancy registries?","volume":"85","author":"Scheuerle","year":"2009","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/bdra.20533","article-title":"Determination of human teratogenicity by the astute clinician method: review of illustrative agents and a proposal of guidelines","volume":"85","author":"Carey","year":"2009","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.38368","article-title":"Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study","volume":"66","author":"Weber-Schoendorfer","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/uog.12442","article-title":"Miscarriage in contemporary maternal\u2013fetal medicine: targeting clinical dilemmas","volume":"42","author":"Borrell","year":"2013","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.gco.0000194112.86051.26","article-title":"Recurrent miscarriage: pathophysiology and outcome","volume":"17","author":"Carrington","year":"2005","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib19","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/art.39137","article-title":"Brief report: miscarriages in female rheumatoid arthritis patients: associations with serologic findings, disease activity, and antirheumatic drug treatment","volume":"67","author":"Brouwer","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib20","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3899\/jrheum.141553","article-title":"Miscarriage and stillbirth in women with rheumatoid arthritis","volume":"42","author":"Wallenius","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib21","first-page":"1, 3","article-title":"Births: final data for 2008","volume":"59","author":"Martin","year":"2010","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/pds.3744","article-title":"Does the average drug exposure in pregnant women affect pregnancy outcome? A comparison of two approaches to estimate the baseline risks of adverse pregnancy outcome","volume":"24","author":"Wacker","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2796.2010.02239.x","article-title":"Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study","volume":"268","author":"Norgaard","year":"2010","journal-title":"J Intern Med"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib24","first-page":"9","article-title":"High rate of preterm birth in pregnancies complicated by rheumatoid arthritis","volume":"31","author":"Langen","year":"2014","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib25","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/art.24914","article-title":"Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study","volume":"60","author":"de Man","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib26","first-page":"355","article-title":"Women with inflammatory polyarthritis have babies of lower birth weight","volume":"28","author":"Bowden","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/aogs.12324","article-title":"Rheumatoid arthritis and outcomes in first and subsequent births based on data from a national birth registry","volume":"93","author":"Wallenius","year":"2014","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bpobgyn.2015.03.003","article-title":"Autoimmune connective tissue diseases","volume":"29","author":"Ostensen","year":"2015","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib29","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3899\/jrheum.140583","article-title":"Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the organization of teratology information specialists autoimmune diseases in pregnancy project","volume":"42","author":"Bharti","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib30","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1093\/cid\/cis215","article-title":"Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy","volume":"54","author":"Schlagenhauf","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2016.05.004_bib31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eplepsyres.2014.01.021","article-title":"Topiramate monotherapy use in women with and without epilepsy: pregnancy and neonatal outcomes","volume":"108","author":"Castilla-Puentes","year":"2014","journal-title":"Epilepsy Res"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216300567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216300567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T01:38:51Z","timestamp":1557365931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216300567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0049017216300567"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.05.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}